Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Drug Investigation
Published in: Clinical Drug Investigation 1/2001

01-01-2001 | Clinical Pharmacokinetics

Absence of Drug Interaction between Oral Moxifloxacin and Intramuscular Morphine Sulfate in Healthy Volunteers

Authors: Alan S. Hollister, Vipin Agarwal, Brad Dain, Dr John Lettieri

Published in: Clinical Drug Investigation | Issue 1/2001

Login to get access

Abstract

Objective

To determine the effects of intramuscular morphine sulfate on the pharmacokinetics of moxifloxacin.

Design

This was a single-centre, randomised, two-way, nonblinded crossover study in healthy young males and females.

Participants

20 healthy volunteers (15 males, five females) with a mean age of 34 years were enrolled and considered evaluable for the pharmacokinetic analysis.

Methods

Moxifloxacin was given under two conditions separated by a minimum 7-day washout period: alone as a single oral 400mg dose, and immediately following 10mg of intramuscular morphine sulfate. Concentrations of moxifloxacin in serum were determined by a validated HPLC procedure with fluorescence detection.

Outcome Measures and Results

Pharmacokinetic parameters estimated were maximum serum concentration (Cmax), time to reach Cmax (tmax), area under the concentration-time curve from zero to infinity (AUC∞), and terminal elimination half-life (t1/2). The natural logarithms of AUC∞ and Cmax were compared by analysis of variance. The mean moxifloxacin serum concentration vs time profiles were similar between the two treatments. The geometric least square mean Cmax values for moxifloxacin were 3.42 mg/L when given alone vs 2.85 mg/L with morphine, producing a ratio (moxifloxacin with morphine vs moxifloxacin alone) of 0.83, with a 90% confidence interval (CI) about the ratio of 0.71 to 0.98. The geometric mean AUC∞ values for moxifloxacin alone and with morphine were 41.5 and 39.6 mg/L·h; the ratio of means was 0.96, with a 90% CI of 0.87 to 1.04. tmax and t1/2 values for moxifloxacin were unchanged when coadministered with morphine. The single oral dose of moxifloxacin 400mg was well tolerated when taken with and without morphine sulfate.

Conclusions

Administration of a single intramuscular dose of morphine did not reduce the bioavailability or alter the elimination profile of oral moxifloxacin. These results suggest that concurrent administration of intramuscular morphine and oral moxifloxacin is unlikely to reduce the efficacy of the quinolone.
Literature
1.
Woodcock JM, Andrews JM, Boswell FJ, et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997 Jan; 41(1): 101–6PubMed
2.
Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997 Jul; 41(7): 1594–7PubMed
3.
Georgopoulous A, Buxbaum A, Graninger W. Activity of Bay 12-8039 against 1154 clinical isolates of Streptococcus pneumoniae [abstract no. F5]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sep 15–18; New Orleans, LA: 100
4.
Burke T, Villanueva C, Mariano H, et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Ther 1999 Aug; 21(10): 1664–77PubMedCrossRef
5.
Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 2000 Jan; 94(1): 18–27PubMedCrossRef
6.
Patel T, Pearl J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Respir Med 2000 Feb; 94(2): 97–105PubMedCrossRef
7.
Fogarty C, Grossman R, Williams J, et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999 Nov; 16(11): 748–63
8.
Springsklee M, Reiter C, Meyer JM. Safety and tolerability profile of MFX to other community respiratory antibiotics [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 140
9.
Kubitza D, Stass H, Wingender W, et al. Bay 12-8039, a new 8-methoxyquinolone: safety, tolerability and steady-state pharmacokinetics in healthy male volunteers [abstract no. F25]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sep 15–18; New Orleans, LA: 104
10.
Stass H, Kubitza D, Schühly U, et al. Pharmacokinetics (PK) and safety (S) and tolerability (T) of 800mg BAY 12-8039 (BA) administered orally as a single dose [abstract]. Clin Microbiol Infect 1997; 3 Suppl. 2: 87
11.
Stass H, Dalhoff A, Kubitza D, et al. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new-8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998 Aug; 42(8): 2060–5PubMed
12.
Sullivan JT, Woodruff M, Lettieri J, et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999 Aug; 43(11): 2793–7PubMed
13.
Stass H, Halabi A, Delesen H. No dose adjustment needed for patients with renal impairment receiving oral BAY 12-8039 [abstract no. A14]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24–27; San Diego, California
14.
Stass H, Kubitza D, von Bermann K, et al. No dose adjustment is needed for moxifloxacin in subjects suffering from hepatic impairment [abstract]. Clin Microbiol Infect 1999; 5 Suppl. 3: 291
15.
Stass H, Boettcher M, Horstmann R. Study to evaluate the interaction between Bay 12-8039 (BA) and antacids (AN) [abstract no. 3358]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney, Australia: 109
16.
Stass H, Kubitza D. Study to evaluate the interaction between moxifloxacin (M) and iron supplements (FE) [abstract]. Anti-infect Drug Chemother 1998; 16 Suppl. 1: 74
17.
Stass H, Dietrich H, Sachse R. Influence of a four-time dosing of 500 mg probenecid on kinetics of BAY 12-8039 after administration of a single 400 mg dose in healthy male volunteers [abstract no. F154]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sep 28–Oct 1; Toronto, Canada: 172
18.
Stass H, Kubitza D, Schwietert R, et al.Bay 12-8039 (BA) does not interact with theophylline (TH) [abstract no. 3356]. 20th International Congress of Chemotherapy; 1997 Jun 29–Jul 3; Sydney, Australia: 108
19.
Stass H, Ochmann K. Study to evaluate the interaction between Bay 12-8039 (BA) and ranitidine (RA) [abstract no. 3357]. 20th International Congress of Chemotherapy: 1997 Jun 29–Jul 3; Sydney, Australia: 108-9
20.
Müller FO, Hundt HKL, Muir AR, et al. Study to investigate the influence of 400 mg BAY 12-8039 given once daily to healthy volunteers on PK and PD of warfarin [abstract no. A13]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sep 24–27; San Diego, California: 4
21.
Stass H, Kern A. Moxifloxacin — review of clinical pharmacokinetics — metabolism and excretion [abstract no. 132]. 6th International Symposium on New Quinolones: 1998 Nov; Denver, CO: 132
22.
Vincent J, Hunt T, Teng R, et al. The pharmacokinetic effects of coadministration of morphine and trovafloxacin in healthy subjects. Am J Surg 1998 Dec; 176 Suppl. 6A: 32S–8SPubMedCrossRef
23.
Morran C, McArdle C, Pettitt L, et al. Brief report: pharmacokinetics of orally administered ciprofloxacin in abdominal surgery. Am J Med 1989 Nov 30; 87 Suppl. 5A: 86S–8SPubMedCrossRef
24.
Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr 1997 Jul; 702: 163–74CrossRef
25.
Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman Gilman A, Rall TW, Nies AS, et al., editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990: 485–521
Metadata
Title
Absence of Drug Interaction between Oral Moxifloxacin and Intramuscular Morphine Sulfate in Healthy Volunteers
Authors
Alan S. Hollister
Vipin Agarwal
Brad Dain
Dr John Lettieri
Publication date
01-01-2001
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 1/2001
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/00044011-200121010-00011

Other articles of this Issue 1/2001

Clinical Drug Investigation 1/2001 Go to the issue

Clinical Use

Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis

Clinical Use

Efficacy and Tolerability of Three Regimens for Helicobacter pylori Eradication

Clinical Pharmacodynamics

Effects of the Standardised Ginseng Extract G115® in Patients with Chronic Bronchitis

Clinical Pharmacoeconomics

Cost-Benefit Analysis of Amtolmetin-Guacil

Clinical Pharmacodynamics

Comparison of Artemether and Artemether plus Mefloquine in Children with Malaria and Effects on Viability of Plasmodium falciparum Ex vivo

Clinical Pharmacokinetics

Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce